KLK3 and posterior cortical atrophy: Based on the encouraging diagnostic presentation and histologically confirmed data in patients with biochemical recurrence PCa, the FDA and European Commission (EC) approved 18F-FACBC for diagnostic imaging in PCa patients with elevated PSA after pre-treatment (58), and until recently, 18F-FACBC imaging has been included in the National Comprehensive Cancer Network (NCCN) guidelines for the management of BCR of PCa.